Sugi Predict

Sugi Predict / Compounds / SCHEMBL4675341

SCHEMBL4675341

SCHEMBL4675341

Cc1ccc(C)n1-c1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ MYC P01106 2/20 0.46
▸ PDCD1 Q15116 1/20 0.44
▸ CD274 Q9NZQ7 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ PLD1 Q13393 1/20 0.42
▸ POLB P06746 2/20 0.41
▸ EP300 Q09472 1/20 0.41
▸ KAT2B Q92831 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ DPP4 P27487 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30436933 1.00 SMN1; SMN2 (0.53) SMN1; SMN2MYCPDCD1CD274KDM4E
SCHEMBL12528726 0.86 SMN1; SMN2 (0.46) SMN1; SMN2MYCPDCD1CD274KDM4E
SCHEMBL30865926 0.79 SMN1; SMN2 (0.40) SMN1; SMN2MYCPDCD1CD274KDM4E
SCHEMBL30865944 0.79 SMN1; SMN2 (0.40) SMN1; SMN2MYCPDCD1CD274KDM4E
SCHEMBL30865948 0.79 SMN1; SMN2 (0.40) SMN1; SMN2MYCPDCD1CD274KDM4E
SCHEMBL7210911 0.77 PTGS2 (0.64) KDM4EALDH1A1HPGD
SCHEMBL29387435 0.75 SMN1; SMN2 (0.43) SMN1; SMN2PDCD1CD274KDM4EALDH1A1
SCHEMBL20033206 0.75 SMN1; SMN2 (0.51) SMN1; SMN2PDCD1CD274KDM4EALDH1A1
SCHEMBL12528830 0.75 SMN1; SMN2 (0.43) SMN1; SMN2PDCD1CD274KDM4EALDH1A1
SCHEMBL4865308 0.75 SMN1; SMN2 (0.43) SMN1; SMN2PDCD1CD274KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111630030-B Novel benzamide derivatives as PPAR-gamma modulators 梅迪比奥法尔玛公司 2023-06-20 — — CN disclosed
US-11267808-B2 Benzamide derivatives as PPAR-gamma modulators MEDIBIOFARMA, S.L. (ES) 2022-03-08 — — US disclosed
EP-3724165-B1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS MEDIBIOFARMA S L (ES) 2022-01-12 — — EP disclosed
US-11059818-B2 Triazolopyridine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-13 — — US disclosed
US-20210171511-A1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS MEDIBIOFARMA, S.L. (ES) 2021-06-10 — — US disclosed
US-11008317-B2 Triazolopyridine inhibitors of myeloperoxidase and/or EPX BRISTOL-MYERS SQUIBB COMPANY (US) 2021-05-18 — — US disclosed
US-20200331910-A1 Mammalian and Bacterial Nitric Oxide Synthase Inhibitors UNIV NORTHWESTERN (US) 2020-10-22 — — US disclosed
US-20200291015-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2020-09-17 — — US disclosed
US-20200291016-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX BRISTOL MYERS SQUIBB CO (US) 2020-09-17 — — US disclosed
CN-111630030-A Novel benzamide derivatives as PPAR-gamma modulators 梅迪比奥法尔玛公司 2020-09-04 — — CN disclosed
US-6051586-A HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS BAYER CORPORATION (US) 2000-04-18 — — US disclosed
WO-2000009130-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 — — WO disclosed
WO-2000002860-A1 2-AMINOPYRIDINE ERIVATIVES, THEIR USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-01-20 — — WO disclosed
EP-0946512-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS PFIZER INC. (US) 1999-10-06 — — EP disclosed
WO-1999032475-A1 NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS BAYER CORPORATION (US) 1999-07-01 — — WO disclosed
CN-1215391-A 6-phenylpyridyl-2-amine derivatives PFIZER (US) 1999-04-28 — — CN disclosed
EP-0891332-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1999-01-20 — — EP disclosed
WO-1998024766-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS PFIZER INC. (US) 1998-06-11 — — WO disclosed
WO-1997036871-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1997-10-09 — — WO disclosed
EP-0385941-A2 Corrosion-resistant compositions CIBA-GEIGY AG (CH) 1990-09-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171511-A1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS PPARD, PPARG, PPARA SMN1; SMN2 3036/4885MYC 3350/4885PDCD1 619/4885
US-20200331910-A1 Mammalian and Bacterial Nitric Oxide Synthase Inhibitors NOS1, NOS2, NOS3 SMN1; SMN2 2936/4885MYC 2236/4885PDCD1 4620/4885
US-20200291015-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE MPO, NOX5, SERPINB1 SMN1; SMN2 4752/4885MYC 4561/4885PDCD1 2431/4885
US-11267808-B2 Benzamide derivatives as PPAR-gamma modulators PPARG, PPARD, PPARA SMN1; SMN2 2885/4885MYC 2973/4885PDCD1 661/4885
US-20200291016-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX EPX, MPO, SERPINB1 SMN1; SMN2 4786/4885MYC 4721/4885PDCD1 2011/4885
US-11008317-B2 Triazolopyridine inhibitors of myeloperoxidase and/or EPX EPX, MPO, SERPINB1 SMN1; SMN2 4786/4885MYC 4721/4885PDCD1 2011/4885
US-11059818-B2 Triazolopyridine inhibitors of myeloperoxidase MPO, NOX5, SERPINB1 SMN1; SMN2 4752/4885MYC 4561/4885PDCD1 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.